Cell therapy · eu
Early ELC-301 lymphoma trial: 8 of 12 patients achieve complete metabolic responses
A new CAR-T therapy has shown preliminary signs of remission in lymphoma patients who have undergone multiple lines of treatment, with some responses lasting more than a year. But results from twelve patients remain a long way from establishing long-term efficacy and safety.
When lymphoma relapses after multiple rounds of treatment, whether the next therapy can deliver lasting remission often matters more than temporary tumor shrinkage. Sweden’s Elicera Therapeutics announced on October 12 that the phase I CARMA trial of its CAR-T cell therapy ELC-301 had been completed. Eight of twelve patients achieved a complete metabolic response at some point, and six maintained that response at their most recent assessment. This offers a preliminary signal for patients with limited treatment options and moves the study into its next stage.
CARMA enrolled patients with relapsed or refractory B-cell lymphoma who had received at least two lines of standard treatment and had no remaining curative treatment options. According to the company announcement and reporting by Nordic Life Science, the study was conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. The twelve patients were divided among three escalating-dose cohorts, and some had previously undergone stem cell transplantation or CAR-T therapy.
The “complete metabolic response” achieved by eight patients means that no metabolically active disease was detected at the time of assessment; it does not mean the cancer has been permanently eliminated. The company said eleven patients had an objective tumor response, meaning a reduction in tumor burden, and all twelve achieved disease control. However, two of the eight complete responders subsequently experienced disease progression. One patient’s complete metabolic response was confirmed to have lasted at least eighteen months, and another’s at least twelve months. These individual follow-up findings offer clues about durability but cannot yet represent the long-term outlook for the overall patient group.
Another signal requiring validation in a larger group comes from three patients who had previously received CAR-T therapy and subsequently relapsed. According to the company announcement, all three achieved disease control after receiving ELC-301, and two had objective responses, including one complete metabolic response. This suggests that patients who relapse after prior CAR-T therapy may still respond, but data from just three patients cannot establish which patients are most likely to benefit.
ELC-301 targets CD20 on the surface of B cells by modifying patients’ T cells to find and attack cancer cells carrying that marker. It also incorporates Elicera’s iTANK platform, which enables the modified cells to secrete a bacterial protein intended to trigger a broader antitumor immune response. However, the clinical data released this time are not yet sufficient to establish independently how much additional efficacy iTANK provides.
On safety, no dose-limiting toxicities were observed in any of the three dose cohorts, supporting continued development. This does not mean the treatment has no side effects, nor does it rule out less common or later-emerging risks. The available information comes primarily from the company announcement. All twelve patients completed at least an efficacy assessment one month after treatment, but the announcement did not provide the distribution of follow-up durations across the group, complete adverse event data, or a comparison with a control group. The full analysis has yet to be released.
The Swedish Medical Products Agency has approved a substantial amendment to the clinical trial authorization, allowing CARMA to enter a phase IIa expansion stage. The study is expected to enroll six additional patients, with enrollment beginning in the fourth quarter of 2026. Next, the study will need to connect the deep remissions seen in a small number of patients with more consistent data on response duration and safety to gradually clarify ELC-301’s therapeutic value in this group of patients with refractory disease.